What is HC Wainwright’s Forecast for ZVRA Q1 Earnings?

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Stock analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Zevra Therapeutics in a report issued on Thursday, March 13th. HC Wainwright analyst O. Livnat expects that the company will post earnings of ($0.23) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Zevra Therapeutics’ Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.03) EPS and Q4 2025 earnings at $0.01 EPS.

Several other brokerages also recently commented on ZVRA. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 target price on shares of Zevra Therapeutics in a research note on Wednesday. Guggenheim lifted their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday. Canaccord Genuity Group lifted their target price on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Citigroup reaffirmed an “outperform” rating on shares of Zevra Therapeutics in a research note on Wednesday. Eight investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $22.14.

Zevra Therapeutics Stock Up 4.7 %

Shares of NASDAQ ZVRA opened at $8.31 on Friday. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. Zevra Therapeutics has a 52 week low of $4.20 and a 52 week high of $9.76. The firm’s fifty day moving average is $7.93 and its 200 day moving average is $8.15. The company has a market cap of $443.55 million, a price-to-earnings ratio of -4.22 and a beta of 1.98.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The business had revenue of $12.00 million during the quarter, compared to the consensus estimate of $8.93 million.

Insider Buying and Selling at Zevra Therapeutics

In other news, CFO R. Laduane Clifton sold 11,000 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $86,460.00. Following the sale, the chief financial officer now owns 51,361 shares in the company, valued at approximately $403,697.46. The trade was a 17.64 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Neil F. Mcfarlane sold 61,273 shares of the business’s stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $481,605.78. Following the sale, the chief executive officer now owns 222,060 shares in the company, valued at approximately $1,745,391.60. This trade represents a 21.63 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 85,773 shares of company stock valued at $674,176. 2.40% of the stock is currently owned by company insiders.

Institutional Trading of Zevra Therapeutics

A number of hedge funds have recently modified their holdings of the business. MetLife Investment Management LLC boosted its holdings in shares of Zevra Therapeutics by 8.1% during the 3rd quarter. MetLife Investment Management LLC now owns 22,866 shares of the company’s stock valued at $159,000 after buying an additional 1,717 shares in the last quarter. IFG Advisors LLC boosted its holdings in shares of Zevra Therapeutics by 10.0% during the 4th quarter. IFG Advisors LLC now owns 29,050 shares of the company’s stock valued at $242,000 after buying an additional 2,650 shares in the last quarter. Invesco Ltd. boosted its holdings in shares of Zevra Therapeutics by 19.6% during the 4th quarter. Invesco Ltd. now owns 18,384 shares of the company’s stock valued at $153,000 after buying an additional 3,007 shares in the last quarter. Corebridge Financial Inc. boosted its holdings in shares of Zevra Therapeutics by 16.9% during the 4th quarter. Corebridge Financial Inc. now owns 26,294 shares of the company’s stock valued at $219,000 after buying an additional 3,801 shares in the last quarter. Finally, Squarepoint Ops LLC boosted its holdings in shares of Zevra Therapeutics by 36.1% during the 4th quarter. Squarepoint Ops LLC now owns 16,534 shares of the company’s stock valued at $138,000 after buying an additional 4,384 shares in the last quarter. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.